Sathyavadhi Anveshi, Gupta Anand, Avadhanam Vishnu Mahathi, Lakkireddygari Siva Kumar Reddy
Department of Critical Care Medicine, AIG Asian Institute of Gasteroenterology Hospitals, Gachibowli, Hyderabad, Telangana, India.
Ann Med Surg (Lond). 2022 Jan;73:103033. doi: 10.1016/j.amsu.2021.103033. Epub 2021 Dec 3.
COVID-19 can lead to severe acute respiratory distress syndrome (ARDS) where Veno-Venous Extra Corporeal Membrane Oxygenation (V-V ECMO) may be utilized for patients with severe respiratory failure. Our case report highlights a life threatening complication of V-V ECMO - intracranial hemorrhage (ICH), in a patient being treated for severe COVID-19 ARDS.
A 41-year-old male of Indian ethnicity with no known comorbidities presented with an 8 day history of fever and dyspnoea. The patient was diagnosed with COVID-19 through a positive RT PCR test and his clinical condition progressively deteriorated requiring mechanical ventilation. Inspite of lung protective ventilation strategies and prone ventilation, there was no improvement in oxygenation. Therefore, the patient was placed on extra corporeal life support. On day three of V-V ECMO, the patient developed anisocoria and his GCS dropped to E1VTM1. A non-contrast CT brain scan revealed a large intraparenchymal hemorrhage in the right frontoparietal lobe with an extension into the right lateral and third ventricles leading to an emergency decompressive craniectomy with lax duroplasty.Post intracranial hemorrhage,ECMO support was continued without systemic anticoagulation. Despite a transient improvement in his GCS post surgery, the patient eventually succumbed to refractory septic shock with multi organ dysfunction syndrome.
Balancing anticoagulation therapy is one of the biggest challenges in managing ECMO support for COVID-19 ARDS. ICH is a rare and potentially fatal complication of V-V ECMO with an apparently higher incidence among COVID-19 patients. Neurosurgical procedures may be considered in such patients when no other possible management strategies are available (and the risk of death is imminent).
新型冠状病毒肺炎(COVID-19)可导致严重急性呼吸窘迫综合征(ARDS),对于严重呼吸衰竭患者可采用静脉-静脉体外膜肺氧合(V-V ECMO)治疗。我们的病例报告强调了一名正在接受重症COVID-19 ARDS治疗的患者发生的V-V ECMO危及生命的并发症——颅内出血(ICH)。
一名41岁无已知合并症的印度裔男性,有8天发热和呼吸困难病史。通过逆转录聚合酶链反应(RT PCR)检测呈阳性确诊为COVID-19,其临床状况逐渐恶化,需要机械通气。尽管采取了肺保护性通气策略和俯卧位通气,氧合仍无改善。因此,该患者接受了体外生命支持。在V-V ECMO治疗的第三天,患者出现瞳孔不等大,格拉斯哥昏迷评分(GCS)降至E1VTM1。脑部非增强CT扫描显示右侧额顶叶有一大块脑实质内出血,并延伸至右侧侧脑室和第三脑室,导致紧急减压性颅骨切除术并行硬脑膜成形术。颅内出血后,在未进行全身抗凝的情况下继续进行ECMO支持。尽管术后患者的GCS有短暂改善,但最终死于难治性感染性休克伴多器官功能障碍综合征。
在管理COVID-19 ARDS的ECMO支持中,平衡抗凝治疗是最大的挑战之一。ICH是V-V ECMO罕见且可能致命的并发症,在COVID-19患者中发生率明显更高。当没有其他可能的管理策略可用(且死亡风险迫在眉睫)时,可考虑对此类患者进行神经外科手术。